These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 34647988)

  • 1. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
    JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobocertinib: Mechanism of action, clinical, and translational science.
    Hanley MJ; Camidge DR; Fram RJ; Gupta N
    Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
    Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
    Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes.
    Arnold A; Ganti AK
    Onco Targets Ther; 2023; 16():559-569. PubMed ID: 37456145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
    Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
    Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobocertinib (TAK-788): A Targeted Inhibitor of
    Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
    Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
    JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for
    Yang JC; Zhou C; Jänne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR; Felip E; Bazhenova L; Jin S; Kaur M; Diderichsen PM; Gupta N; Bunn V; Lin J; N Churchill E; Mehta M; Nguyen D
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):95-106. PubMed ID: 36537204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
    Gupta N; Largajolli A; Witjes H; Diderichsen PM; Zhang S; Hanley MJ; Lin J; Mehta M
    Clin Pharmacol Ther; 2022 Aug; 112(2):327-334. PubMed ID: 35467009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
    Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
    Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
    [No Abstract]   [Full Text] [Related]  

  • 11. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
    Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
    Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
    J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
    Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
    Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
    Wang M; Fan Y; Sun M; Wang Y; Zhao Y; Jin B; Hu Y; Han Z; Song X; Liu A; Tang K; Ding C; Liang L; Wu L; Gao J; Wang J; Cheng Y; Zhou J; He Y; Dong X; Yao Y; Yu Y; Wang H; Sun S; Huang J; Fang J; Li W; Wang L; Ren X; Zhou C; Hu Y; Zhao D; Yang R; Xu F; Huang Y; Pan Y; Cui J; Xu Y; Yang Z; Shi Y
    Lancet Respir Med; 2024 Mar; 12(3):217-224. PubMed ID: 38101437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    Mazieres J; Paik PK; Garassino MC; Le X; Sakai H; Veillon R; Smit EF; Cortot AB; Raskin J; Viteri S; Wu YL; Yang JCH; Ahn MJ; Ma R; Zhao J; O'Brate A; Berghoff K; Bruns R; Otto G; Johne A; Felip E; Thomas M
    JAMA Oncol; 2023 Sep; 9(9):1260-1266. PubMed ID: 37270698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy and safety of mobocertinib in
    Kian W; Christopoulos P; Remilah AA; Levison E; Dudnik E; Shalata W; Krayim B; Marei R; Yakobson A; Faehling M; Kahala D; Sara Granot I; Levitas D; Peled N; Roisman LC
    Front Oncol; 2022; 12():1010311. PubMed ID: 36203432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
    Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobocertinib (TAK-788) in
    Garcia Campelo MR; Zhou C; Ramalingam SS; Lin HM; Kim TM; Riely GJ; Mekhail T; Nguyen D; Goodman E; Mehta M; Popat S; Jänne PA
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
    Tan DSW; Kim SW; Ponce Aix S; Sequist LV; Smit EF; Yang JCH; Hida T; Toyozawa R; Felip E; Wolf J; Grohé C; Leighl NB; Riely G; Cui X; Zou M; Ghebremariam S; O'Sullivan-Djentuh L; Belli R; Giovannini M; Kim DW
    Eur J Cancer; 2022 Sep; 172():276-286. PubMed ID: 35810553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.